Business Wire

IFFE FUTURA, Listed on the BME GROWTH, Invests 18 Million Euros in Its Omega 3 Plant

Share

IFFE FUTURA (www.iffefutura.es), an industrial and services group based in Galicia (Spain) and listed on BME GROWTH, has signed a financing commitment of 18 million euros with several investors led by INVEREADY. The objective of this financing is to complete the Omega 3 production facilities, based in As Somozas (Galicia), and start marketing Omega 3 B2B from 2023 to functional food companies for nutritional supplements, pharmaceutical products, cosmetics and animal food, among others. The new facilities will have a capacity of more than 10,000 tons per year of Omega 3 of the highest quality and better organoleptic behaviour.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220617005479/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

IFFE Futura headquarters in Galicia (Spain). Source: IFFE Future

The financing partners have been led by INVEREADY, which invests 9 million euros through hybrid funds, and a group of investors who are experts in investing in BME GROWTH, who invest 4 million euros in their own funds. In addition, IFFE FUTURA has obtained financing from Banco Sabadell, for an amount of up to 4 million euros, and from Xunta de Galicia (through XesGalicia), for an amount of up to 1.25 million euros.

The operation is completed with the entry of NATAC Group as a minority shareholder of IFFE BIOTECH. NATAC Group, a leading company in the natural ingredients sector, will support IFFE BIOTECH in the completion of the Omega 3 production facilities and will be a partner in the distribution of IFFE BIOTECH's final production. NATAC Group will also contribute patents related to Omega 3 to IFFE BIOTECH.

IFFE BIOTECH will have a new board of directors made up of IFFE FUTURA, NATAC Group and Inveready.

David Carro, CEO of the Group, declared: "The support of INVEREADY and its co-investors, as financial leaders of the operation; of XESGALICIA, showing the support of the Galician regional government; and the municipality of As Somozas, added to the financial loan obtained from Banco Sabadell, ensure the success of our plan strategic and sustained growth of the Company for several years. In addition, this project enhances the value of the primary sector industry, such as fishing, and will bring about the generation of employment in the area.”

www.iffefutura.es

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

IFFE FUTURA, SA
DAVID CARRO
+34 881.89.60.49
INVESTORS@IFFEFUTURA.ES

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

The Patient Safety Movement Foundation Concludes Its 10th Annual World Patient Safety, Science & Technology Summit3.6.2023 08:11:00 EEST | Press release

President Bill Clinton, 42nd President of the United States, headlined day two of the 10th Annual World Patient Safety, Science & Technology Summit, presented by the Patient Safety Movement Foundation (PSMF). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230602005417/en/ Joe Kiani, founder of the Patient Safety Movement Foundation, discusses efforts to improve patient safety worldwide with former President Bill Clinton at the 10th Annual World Patient Safety, Science & Technology Summit in Newport Beach, California. (Photo: Business Wire) As a long-time advocate of patient safety, President Clinton spoke of the need to develop what he termed a “culture of conversion,” where more people within healthcare feel empowered to implement proven practices for eliminating preventable harm within hospitals. “We know enough right now to cut the current problem by half or more,” he said. “One of the biggest problems you have in every b

Ilsong Educational Foundation Chairman Dai-Won Yoon Wins Linnaeus Medal as the First in Asia2.6.2023 12:00:00 EEST | Press release

On May 30, Chairman Dai-Won Yoon of Ilsong Educational Foundation received the Linnaeus Medal from Uppsala University at Hallym University. This makes him the first person from Asia to receive the award. Ilsong Educational Foundation operates Hallym University and Hallym University Medical Center. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230531005495/en/ Chairman Dai-Won Yoon (left) of Ilsong Educational Foundation received Linnaeus Medal as the 1st in Asia (Photo: Hallym University) Chairman Yoon is the honoree of 2020. The award ceremony, which had been postponed due to COVID-19, was held this year with a delegation led by Vice Chancellor Anders Hagfeldt of Uppsala University visiting Korea. The Linnaeus Medal to commemorate Carl Linnaeus, a Swedish botanist, is awarded annually by Uppsala University to a person who has made a significant contribution to the field of science. Chairman Yoon was honored for his work in

10th Annual World Patient Safety, Science & Technology Summit Begins2.6.2023 09:15:00 EEST | Press release

Day one of the 10th Annual World Patient Safety, Science & Technology Summit presented by the Patient Safety Movement Foundation (PSMF) saw global leaders across the world of patient safety call for an increased urgency in addressing the issue of preventable harm within healthcare. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230601006140/en/ Joe Kiani, founder of the Patient Safety Movement Foundation, speaks at the 10th Annual World Patient Safety, Science & Technology Summit in Newport Beach, California. (Photo: Business Wire) Celebrating the PSMF’s 10th anniversary, Dr. Michael Ramsay, chief executive officer of the PSMF, reflected on the role that the increasing availability of hospital data on medical errors could play in reducing harm. “I’m very optimistic that we’re really going to see a difference in healthcare,” he said. “Technology is changing. We’re now getting real data. We know what the outcomes are in hospit

Autel Energy Holds Partner Summit in Amsterdam, Mapping Out Europe Strategy2.6.2023 09:00:00 EEST | Press release

Autel Energy, a leading provider of EV charging products and services, successfully hosted the Autel Partner Summit at Muziekgebouw in Amsterdam from May 31 to June 1, 2023. The event not only showcased Autel’s visionary Europe strategy for the next two years but also provided partners opportunities to gain insights into the company's vision, and learn about Autel’s new products. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230525005428/en/ A quick afternoon bite with the Autel partners. (Photo: Business Wire) The Partner Summit helped Autel Energy to strengthen its partnerships in Europe and highlighted its collaborations with key clients. Notable partners in attendance included Maxicharger AC clients such as Sevadis and Deta, as well as Maxicharger DC clients such as Floading, Gasgas, and eWays. The company also partnered with CPO clients like Fastway and Powerdo, as well as energy companies like Enefit. The Summit was d

PL BioScience and Macopharma enter into a Patent License and Assignment Agreement regarding Human Platelet Lysate (HPL) cell culture supplements.2.6.2023 08:22:00 EEST | Press release

PL BioScience GmbH, a German life science company specializing in the production and development of Human Platelet Lysate (HPL) for cell expansion, today announced a Patent License and Assignment Agreement with the French company Macopharma S.A.S. As a result of the Agreement, PL BioScience will hereby accept a worldwide license under the patents filed by Macopharma, with a right to sublicense (through multiple tiers), for the duration of the license period. In addition to the Patent License and Assignment Agreement, Macopharma will introduce PL BioScience to their current HPL customers, and thanks to a comprehensive comparative evaluation showing equivalence of HPL products from PL BioScience, Macopharma HPL customers will have the opportunity to transfer their future orders to PL BioScience with minimal disruption. About PL BioScience: Located in Aachen in Germany, PL BioScience GmbH is a life science company specializing in the production and development of Human Platelet Lysate (HP

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom